Merit Medical Systems, Inc. (MMSI)

Over the past year, MMSI stock has decreased by 13.32% and experienced a 0.80% fall over the last month, though it rose by 2.22% in the week leading up to October 24, 2025. The company underperformed the US Medical Equipment industry and the broader US Market over the past year. Recent events include an agreement to acquire the C2 CryoBalloon device from Pentax of America, Inc., which is expected to enhance Merit's endoscopy portfolio. Merit Medical Systems is scheduled to announce its third-quarter 2025 results on October 30, 2025. The company announced that 750,000 patients have been treated with its wire-free SCOUT technology. Merit Medical's Embosphere Microspheres achieved CE Mark for Genicular Artery Embolisation to treat knee osteoarthritis. Updates on ongoing clinical studies for the Surfacer® Inside-Out® Access Catheter System and Bearing nsPVA Embolization Particles for uterine fibroids could positively impact stock performance. In August 2023, the stock experienced a downgrade following acquisitions and flat Q2 numbers, with analysts issuing negative revisions to earnings forecasts, and insider selling has also been noted.

The specific patterns of demand seasonality for Merit Medical Systems' products and services are not detailed in the current snippets. Generally, the medical device industry can experience demand fluctuations based on healthcare spending cycles, budget allocations by hospitals, and the timing of elective procedures, but specific seasonal trends for MMSI are not explicitly stated.

Merit Medical Systems, Inc. (MMSI) is a medical equipment company specializing in disposable medical devices used in interventional, diagnostic, and therapeutic procedures across various medical fields. The company operates within the Health Care sector, specifically in the Medical/Dental Instruments industry, and is segmented into Cardiovascular and Endoscopy. The Cardiovascular segment includes products for peripheral and cardiac intervention, custom procedural solutions, and OEM products, including devices for diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases. The Endoscopy segment includes gastroenterology and pulmonology devices that assist in the palliative treatment of expanding esophageal, tracheobronchial, and biliary strictures.

Merit Medical Systems serves hospitals and physicians globally and employs approximately 7,000 people worldwide. The company has manufacturing facilities in various locations, including South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Aliso Viejo, California; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore. It also has distribution centers in Maastricht and Venlo, The Netherlands, and sales offices across North America, Europe, the Middle East, Africa, Asia, and Latin America.

Merit Medical Systems has an established reputation for high-quality and innovative products, backed by a commitment to research and development. The company has built strong brand recognition for reliability and excellence over more than three decades in the industry. In 2023, Barron's recognized Merit as one of the 100 most sustainable companies in the United States, highlighting its focus on sustainability and corporate responsibility. No specific negative events significantly impacting its brand reputation in the past year were identified in the provided information.

Merit Medical Systems (MMSI) stock ownership is primarily held by institutional investors, who own approximately 41.81% to 90.92% of the company's stock. Insiders own about 2.47% to 5.49%, and retail investors or public companies and individual investors hold the remaining shares. Major institutional owners include Blackrock Inc., Vanguard Group Inc., Fmr LLC, and State Street Corp. The largest individual shareholder is Fred P. Lampropoulos, who owns 1.49 million shares, representing 2.51% of the company.